Semma Therapeutics

Semma Therapeutics is a regenerative medicine development biotechnology company primarily focused on developing groundbreaking stem cell therapies. Its patented technology can generate billions of functional β cells capable of producing insulin, which have the potential to control blood sugar levels in diabetes patients. The current standard treatment for T1DM involves the use of insulin pumps or multiple daily insulin injections. However, insulin injections do not offer a cure, and patients often require lifelong treatment while facing severe complications such as kidney failure, blindness, and nerve damage.